99P Circulating tumor DNA as a biomarker for neratinib and trastuzumab efficacy in HER2-mutated advanced solid tumors: Insights from KCSG AL20-17/KM23 phase II trial
Year: 2024
Type: article
Source: Annals of Oncology
Authors: K. Lee, K-H. Lee, D-W. Kim, J.S. Yoon, W. Choi, Y. Lee, Y.J. Choi, S. Lee, J.W. Kim, H. Ryu, D-H. Koo, Y-G. Lee, H-C. Jeung, M-Y. Lee, N. Lee, M.J. Kang, J. Lee, S-H. Hong, E.J. Kang, I.H. Park
Institutions: Seoul National University Hospital, Korea University Guro Hospital, National Cancer Center, Kangbuk Samsung Hospital, Sungkyunkwan University, Korea University Anam Hospital, Chungnam National University Hospital, Yonsei University, Gangnam Severance Hospital, Yonsei University Health System, Soonchunhyang University, Soonchunhyang University Hospital Seoul, Inje University Haeundae Paik Hospital, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: bronze
Funder: Ministry of Health and Welfare
Award: G4526455045
OpenAlex ID: W4402561571